Warning: file_put_contents(/srv/users/serverpilot/apps/bitupdateus/public/wp-content/plugins/bulk-post-0.4-1/cache/sessions//10fVGYekELUhasLnTX9g8V9RFOARBfexJaV3hACu): failed to open stream: No space left on device in /srv/users/serverpilot/apps/bitupdateus/public/wp-content/plugins/stupidpie-1.8.3-1/vendor/illuminate/filesystem/Filesystem.php on line 122
  GNW News: GW Pharmaceuticals Announces Planned Public Offering of American Depositary Shares | News | Bit Updates
Home » bitcoin updates » GNW News: GW Pharmaceuticals Announces Planned Public Offering of American Depositary Shares | News

GNW News: GW Pharmaceuticals Announces Planned Public Offering of American Depositary Shares | News

Thursday, December 7th, 2017 | bitcoin updates

GW Pharmaceuticals Announces Scheduled Public Offering of American Depositary Shares LONDON, Dec. 7, 2017 (GLOBE NEWSWIRE) – GW Pharmaceuticals plc ("GW" or the "Company"), a biopharmaceutical company, specializing in the discovery, development and commercialization of novel therapeutics from its proprietary cannabinoid product platform, announced today that it will, subject to market and other conditions, sell US $ 225 million worth of American Deposits Shares ("ADSs") on the NASDAQ Global Market within the framework of a guaranteed public offering in the United States. These ADSs represent common shares of GW. GW anticipates that it will provide the underwriters with a 30-day option to purchase additional ADSs of up to $ 33.75 million at the offer price. No firm statement can be made as to whether and when the offer can be closed, or what scope and what conditions the offer will actually have. Goldman Sachs & Co., LLC, Morgan Stanley, BofA Merrill Lynch, and Cowen have all acted as consortium leaders for the Offer. The ADSs described above are being acquired by GW pursuant to a filing by GW with the Securities and Exchange Commission ("SEC ") filed Shelf Registration Statement, which came into force on 17 April 2017 automatically, offered. A preliminary prospectus supplement to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the Provisional Supplements and Supplementary Prospectus relating to this Offering may be obtained upon availability of the following addresses: GoldmanSachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY10282, Phone: 1-866-471-2526, Fax: 212-902-9316 or e-mail: prospectusgroup-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3 (rd) Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, Email: dg.prospectus_requests@baml.com; Cowenand Company, LLC, Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717 Attn: Prospectus Department, 1-631-274-2806. This press release is not an offer of sale or solicitation of an offer to buy and these securities are not sold in any jurisdiction or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or any such jurisdiction. The ADSs will not become public in the United Kingdom for sale. This news release is not intended for distribution to or use by any person or entity who is or is located in a place, state, country, or other jurisdiction in which such distribution, publication, availability, or use would violate any law or regulation or in which a registration or licensing would be required. The distribution of this press release in jurisdictions other than the United Kingdom may be restricted by law. Persons in possession of this notice should inform themselves about and comply with such restrictions.For readers in the European Economic AreaIn any EEA Member State which has implemented the Prospectus Directive, this notice is addressed only to qualified investors in that Member State within the scope of the Prospectus Directive. The term "Prospectus Directive" means Directive 2003/71 / EC (and amendments thereto, including Directive 2010/73 / EU, as implemented in the relevant Member State) and all relevant implementing measures in the relevant Member State.For readers in the United KingdomThis Communication, in so far as it A solicitation or incentive to invest (as defined in s21 Financial Services and Markets Act 2000) in relation to the Securities which are the subject of the Offer described in this News Release, is directed to (i) persons outside the United Kingdom or ( (ii) Persons having professional experience in investment matters who are subject to Article 19 (5) ("professional investors") of the Financial Services Order 2000 (Financial Promotion) Order 2005 (the "Decree") or (iii) certain natural and legal persons of high value Article 49 (2) (a) to (d) of the decree, or (iv) any other person to whom it may lawfully be transferred (all of them under (i) to (iv) collectively referred to as "relevant persons"). The ADSs are only available to relevant persons, and any solicitation, offer or agreement to subscribe, buy or otherwise acquire such ADSs occurs Anyone other than a Relevant Person should not act or rely on this document or its contents. About GW Pharmaceuticals plcGW is a biopharmaceutical company founded in 1998 that focuses on the discovery, development and commercialization of novel therapeutics specializes in its own cannabinoid product platform in a wide range of disease areas. GW and its US subsidiary Greenwich Biosciences are driving an orphan drug program in children's epilepsy focused on epidiolex (cannabidiol), for which GW has submitted an NDA to the FDA for the adjuvant treatment of LGS and Dravet syndrome , The Company continues to investigate epidiolex for additional epilepsy disorders and is currently conducting clinical trials in the field of tuberous sclerosis and infantile spasms. GW has launched the world's top-selling prescription herbal cannabinoid drug Sativex® (nabiximole), which is approved in multiple countries outside of the United States for the treatment of multiple sclerosis spasticity. The Company has an extensive pipeline of other cannabinoid product candidates containing active ingredients in Phase 1 and Phase 2 studies in glioblastoma, schizophrenia and epilepsy. Forward-Looking Statements This press release may contain forward-looking statements that reflect GW's current expectations regarding future events, including: Statements regarding the intended public offering of ADSs by GW, including the value of the ADSs GW intends to sell, financial performance, timing of clinical trials, timing and results of regulatory decisions or decisions on intellectual property, the relevance of commercially available and in-process GW Products, the clinical benefits of Epidiolex® (cannabidiol), the safety profile and commercial potential of Epidiolex, and the development and commercialization of Epidiolex Some statements contain risks and uncertainties. Actual events could differ materially from events envisaged herein and depend on a number of factors including, but not limited to, the success of GW's research strategies, the applicability of the discoveries made, the successful and timely execution of the regulatory process and associated uncertainties, and the acceptance of Sativex; Epidiolex and other products by consumers and healthcare professionals. A further list and description of the risks and uncertainties associated with investing in GW can be found in the filings with the US Securities and Exchange Commission, including the most recent Form 20-F, filed on 4 December 2017. Existing and Potential investors are cautioned not to rely on these forward-looking statements because they apply only at the time of this news release. GW undertakes no obligation to update or revise the information contained in this news release, whether as a result of new information, future events or circumstances or otherwise. Inquiries: GW Pharmaceuticals plc (Today) +44 20 3727 1000 Steven Schultz, VP Investor Relations (USA) 917 280 2424/401 500 6570This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: GW Pharmaceuticals plc via GlobeNewswirehttp: //www.gwpharm.com

Related

Peter Steudtner is free:

The flash of lightning flashes for the time being. With nine minutes delay

Nintendo: Strong profit a

                         Game console Nintendo Switch                                                   (Picture: c't)                              

UN Security Council: Vote

The UN Security Council has postponed a vote on a possible ceasefire in

Green Week in Berlin: And

How green is Brandenburg? It is abundant. Answers are in the Statistical Yearbook.